EA199900349A1 - Каталитическая субъединица теломеразы человека - Google Patents
Каталитическая субъединица теломеразы человекаInfo
- Publication number
- EA199900349A1 EA199900349A1 EA199900349A EA199900349A EA199900349A1 EA 199900349 A1 EA199900349 A1 EA 199900349A1 EA 199900349 A EA199900349 A EA 199900349A EA 199900349 A EA199900349 A EA 199900349A EA 199900349 A1 EA199900349 A1 EA 199900349A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- human telomerase
- unit
- human
- catalytic sub
- present
- Prior art date
Links
- 108010017842 Telomerase Proteins 0.000 title 1
- 230000003197 catalytic effect Effects 0.000 title 1
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
Abstract
В настоящем изобретении созданы композиции и способы, имеющие отношение к обратной транскриптазе теломеразы человека (hTRT), к каталитической субъединице теломеразы человека. Полинуклеотиды и полипептиды настоящего изобретения пригодны для диагноза, прогноза и лечения заболеваний человека, для изменения пролиферативной способности клеток и организмов и для идентификации и скринирования соединений и терапий, пригодных для лечения таких заболеваний, как раковые заболевания.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72464396A | 1996-10-01 | 1996-10-01 | |
US84441997A | 1997-04-18 | 1997-04-18 | |
US84601797A | 1997-04-25 | 1997-04-25 | |
US08/851,843 US6093809A (en) | 1996-10-01 | 1997-05-06 | Telomerase |
US08/854,050 US6261836B1 (en) | 1996-10-01 | 1997-05-09 | Telomerase |
US91550397A | 1997-08-14 | 1997-08-14 | |
US91131297A | 1997-08-14 | 1997-08-14 | |
US08/912,951 US6475789B1 (en) | 1996-10-01 | 1997-08-14 | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
PCT/US1997/017885 WO1998014593A2 (en) | 1996-10-01 | 1997-10-01 | Human telomerase catalytic subunit |
Publications (1)
Publication Number | Publication Date |
---|---|
EA199900349A1 true EA199900349A1 (ru) | 2000-06-26 |
Family
ID=27575511
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199900355A EA199900355A1 (ru) | 1996-10-01 | 1997-10-01 | Теломераза обратная тринскриптаза |
EA199900349A EA199900349A1 (ru) | 1996-10-01 | 1997-10-01 | Каталитическая субъединица теломеразы человека |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199900355A EA199900355A1 (ru) | 1996-10-01 | 1997-10-01 | Теломераза обратная тринскриптаза |
Country Status (21)
Country | Link |
---|---|
US (4) | US6166178A (ru) |
EP (6) | EP0954585B1 (ru) |
JP (7) | JP2001523947A (ru) |
KR (2) | KR20000048820A (ru) |
CN (3) | CN102021153B (ru) |
AT (3) | ATE245194T1 (ru) |
AU (2) | AU734089B2 (ru) |
BR (3) | BR9711844A (ru) |
CA (3) | CA2645721C (ru) |
DE (5) | DE19743497A1 (ru) |
EA (2) | EA199900355A1 (ru) |
ES (1) | ES2205132T5 (ru) |
FI (1) | FI990655A0 (ru) |
FR (1) | FR2757177A1 (ru) |
GB (2) | GB2317891C (ru) |
HK (1) | HK1156967A1 (ru) |
IL (2) | IL129222A0 (ru) |
NO (2) | NO319982B1 (ru) |
NZ (1) | NZ334709A (ru) |
SG (1) | SG94355A1 (ru) |
WO (2) | WO1998014593A2 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2581800C2 (ru) * | 2010-02-16 | 2016-04-20 | Ультимовакс Ас | Полипептиды |
Families Citing this family (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
US6545133B1 (en) | 1995-08-04 | 2003-04-08 | Geron Corporation | Methods for purifying telomerase |
US6517834B1 (en) * | 1995-08-04 | 2003-02-11 | Geron Corporation | Purified telomerase |
ATE219151T1 (de) | 1995-11-16 | 2002-06-15 | Michael W Dahm | Verfahren zur quantifizierung von tumorzellen in einer körperflüssigkeit und dazu geeignete testkits |
US6881571B1 (en) * | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
US6607898B1 (en) | 1996-03-26 | 2003-08-19 | Oncomedx, Inc. | Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum |
US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
US6444650B1 (en) * | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
US6808880B2 (en) | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
US6777203B1 (en) | 1997-11-19 | 2004-08-17 | Geron Corporation | Telomerase promoter driving expression of therapeutic gene sequences |
US6261836B1 (en) * | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
EP0954585B1 (en) | 1996-10-01 | 2009-11-25 | Geron Corporation | Human telomerase reverse transcriptase promoter |
US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
US7390891B1 (en) | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
EP0942991A2 (en) * | 1996-11-26 | 1999-09-22 | Baylor College Of Medicine | Identification of inhibitors that prevent access of telomerase to chromosomal terminus |
WO1998037181A2 (en) * | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
US7413864B2 (en) | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
US20050013825A1 (en) * | 1997-04-18 | 2005-01-20 | Geron Corporation | Vaccine containing the catalytic subunit of telomerase for treating cancer |
EP0990037A2 (de) * | 1997-06-20 | 2000-04-05 | Bayer Ag | Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung |
EP1571215A3 (en) * | 1997-07-01 | 2007-10-31 | Cambia Biosystems LLC | Vertebrate telomerase genes and proteins and uses thereof |
KR100581990B1 (ko) * | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
US7378244B2 (en) * | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
WO1999027113A1 (en) * | 1997-11-26 | 1999-06-03 | Geron Corporation | Mouse telomerase reverse transcriptase |
DE19757984A1 (de) * | 1997-12-24 | 1999-07-01 | Bayer Ag | Regulatorische DNA-Sequenzen aus der 5'-Region vom Gen der humanen katalytischen Telomerase-Untereinheit udn deren diagnostische und therapeutische Verwendung |
DE19804372A1 (de) | 1998-02-04 | 1999-08-05 | Michael W Dr Dr Dahm | Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits |
US6639057B1 (en) | 1998-03-26 | 2003-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Monoclonal antibody against human telomerase catalytic subunit |
US6337200B1 (en) * | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
JP2002509716A (ja) | 1998-03-31 | 2002-04-02 | ユニバーシティ テクノロジー コーポレイション | テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物 |
US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
US20030105315A1 (en) * | 1998-04-09 | 2003-06-05 | Metagen Pharmaceuticals Gmbh | Human nucleic acid sequences from ovarian tumor tissue |
US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
WO2000025813A1 (en) | 1998-10-29 | 2000-05-11 | Dana-Farber Cancer Institute | CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT |
GB9900298D0 (en) * | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
WO2000043501A2 (de) * | 1999-01-22 | 2000-07-27 | Humboldt-Universität Zu Berlin Universitätsklinikum Charite | GEGEN DIE KATALYTISCHE UNTEREINHEIT DER HUMANEN TELOMERASE (hTERT) GERICHTETE RIBOZYME |
EP1147181B1 (en) * | 1999-02-04 | 2004-05-12 | Geron Corporation | Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer |
US8114850B2 (en) | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
EP1181304B1 (en) | 1999-04-08 | 2007-10-10 | Antisoma Research Limited | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
US7960540B2 (en) | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
CA2368967A1 (en) * | 1999-04-09 | 2000-10-19 | Biomira, Inc. | Telomerase-specific cancer vaccine |
US6358739B1 (en) * | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
DE19916929A1 (de) | 1999-04-15 | 2000-10-19 | Bayer Ag | Ein automatisierbarer Schnelltest zum Nachweis von Krebserkrankungen auf der Basis von Telomerase(hTC) mRNA mit spezifischen Primern und Sonden |
US6995145B1 (en) | 1999-06-04 | 2006-02-07 | Au Jessie L-S | Methods and compositions for modulating drug activity through telomere damage |
US20050255596A1 (en) * | 1999-09-07 | 2005-11-17 | West Michael D | Methods of repairing tandemly repeated DNA sequences and extending cell life-span nuclear transfer |
CA2382521C (en) | 1999-09-10 | 2009-08-25 | Sergei Gryaznov | Oligonucleotide n3'.fwdarw.p5' thiophosphoramidates: their synthesis and use |
FR2798673B1 (fr) * | 1999-09-16 | 2004-05-28 | Exonhit Therapeutics Sa | Methodes et compositions pour la detection d'evenements pathologiques |
US6399384B1 (en) | 1999-09-17 | 2002-06-04 | Reneuron Limited | Conditional immortalization of cells |
WO2001036971A1 (fr) * | 1999-11-16 | 2001-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Methode de recherche de substance d'inhibition de liaison entre des sous-unites de telomerase |
GB9927353D0 (en) * | 1999-11-19 | 2000-01-19 | Cantab Pharma Res | Virus preparation and use |
US6664046B1 (en) * | 1999-12-16 | 2003-12-16 | Roche Molecular Systems, Inc. | Quantitation of hTERT mRNA expression |
KR20010096991A (ko) * | 2000-04-19 | 2001-11-08 | 임정빈 | 텔로머레이즈의 프로모터에 특정하게 결합하는더블유티이1 절편, 그 유전자, 발현벡터 및 그것을 이용한세포성장 억제 방법 |
US6458589B1 (en) | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
IT1318504B1 (it) * | 2000-05-08 | 2003-08-27 | Talent Srl | Metodo e apparecchiatura per la diagnosi precoce di tumori vescicalisu campioni di urina. |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
US6492171B2 (en) * | 2000-05-16 | 2002-12-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of TERT expression |
US7250294B2 (en) | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
EP1158055A1 (fr) | 2000-05-26 | 2001-11-28 | Xu Qi University of Teaxs Laboratoire de Leucémie Chen | Méthode pour le diagnostic de cancers |
US7078491B1 (en) | 2000-09-21 | 2006-07-18 | Amgen Inc. | Selective binding agents of telomerase |
US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
US6713055B2 (en) | 2000-11-27 | 2004-03-30 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
AU2002226076A1 (en) * | 2000-12-14 | 2002-06-24 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Telomerase immortalized human liver cell lines |
US6906237B2 (en) * | 2001-02-27 | 2005-06-14 | G. Scott Herron | Vivo assay for anti angiogenic compounds |
US20040063922A1 (en) * | 2001-04-17 | 2004-04-01 | Conrad Charles A. | Methods and compositions for catalytic DNA exchange in a sequence specific manner |
US7262174B2 (en) * | 2001-05-09 | 2007-08-28 | Geron Corporation | Treatment for wounds |
GB0112342D0 (en) * | 2001-05-21 | 2001-07-11 | Norsk Hydro As | Polypeptides |
US7291499B2 (en) | 2001-07-16 | 2007-11-06 | Fuyuki Ishikawa | Transformed cell, method of screening anti-aging agent and anti-aging agent |
US7150989B2 (en) * | 2001-08-10 | 2006-12-19 | Cornell Research Foundation, Inc. | Telomerase immortalized neural progenitor cells |
AUPR769701A0 (en) * | 2001-09-14 | 2001-10-11 | Li, He | Telomerase inhibitory peptides and uses thereof |
EP1440085B8 (de) * | 2001-10-18 | 2010-08-04 | Medicyte GmbH | Transiente immortalisierung von zellen durch onkogenproteine oder telomerproteine |
CA2478681A1 (en) * | 2001-10-22 | 2003-05-01 | University Of Rochester | Telomerase interference |
WO2003038076A1 (fr) * | 2001-10-31 | 2003-05-08 | Renomedix Institute Inc. | Cellules mesenchymateuses immortalisees et leur utilisation |
CA2470539C (en) * | 2001-12-07 | 2011-10-04 | Geron Corporation | Islet cells from human embryonic stem cells |
US20030153082A1 (en) | 2001-12-07 | 2003-08-14 | The John P. Robarts Research Institute | Hematopoietic cells from human embryonic stem cells |
DE10163130B4 (de) * | 2001-12-20 | 2009-05-14 | Cyto Tools Gmbh | Apoptotisch wirksame Peptide und diese umfassende pharmazeutische Zusammensetzungen |
WO2003054545A1 (fr) * | 2001-12-21 | 2003-07-03 | Mitsubishi Kagaku Iatron, Inc. | Procede permettant de detecter un anticorps anti-telomerase |
GB0200929D0 (en) * | 2002-01-16 | 2002-03-06 | Univ Glasgow | Tissue rejection |
ATE548461T1 (de) * | 2002-01-18 | 2012-03-15 | Morphotek Inc | Verfahren zur erzeugung manipulierter zellen zur locus-spezifischen genregulation und analyse |
US20030175961A1 (en) * | 2002-02-26 | 2003-09-18 | Herron G. Scott | Immortal micorvascular endothelial cells and uses thereof |
US20050106729A1 (en) * | 2002-05-03 | 2005-05-19 | Mark Irvin Rosenblatt | Gene transfer methods and compositions |
EP1513865A4 (en) * | 2002-05-28 | 2006-05-03 | Univ Minnesota | CRISP POLYPEPTIDES AS PREVENTIONAL AND INHIBITORS OF SPERM CAPACITATION |
US7294708B2 (en) * | 2002-05-31 | 2007-11-13 | Beijing Institute Of Biotechnology | Telomerase reverse transcriptase fragments and uses thereof |
CA2488924A1 (en) * | 2002-06-18 | 2003-12-24 | Zymogenetics, Inc. | Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter |
US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
AU2003290689A1 (en) | 2002-11-08 | 2004-06-03 | Kyowa Hakko Kirin Co., Ltd. | Transgenic ungulates having reduced prion protein activity and uses thereof |
US7166692B2 (en) | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
WO2004099385A2 (en) * | 2003-04-30 | 2004-11-18 | Duke University | Telomere elongation |
KR101465515B1 (ko) | 2003-06-23 | 2014-11-26 | 텔로머레이스 엑티베이션 사이언시즈, 인코퍼레이티드 | 텔로머라제 활성을 증가시키기 위한 조성물 및 방법 |
EP1664098A1 (en) * | 2003-09-12 | 2006-06-07 | Reneuron Limited | Immortalisation of mammalian cells and therapeutic applications of said cells |
EP1522858A1 (en) * | 2003-10-10 | 2005-04-13 | Jean-Christophe Roegel | Methods for selecting compounds using antibodies with activity as agonist, antagonist or allosteric modulators |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
NZ550106A (en) | 2004-04-22 | 2009-06-26 | Kyowa Hakko Kirin Co Ltd | Transgenic animals and uses thereof |
DE602005025106D1 (de) | 2004-05-11 | 2011-01-13 | Axiogenesis Ag | Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen |
EP1781337A4 (en) * | 2004-08-05 | 2010-06-23 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR CELL ACTIVATION |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
JP2006242618A (ja) * | 2005-03-01 | 2006-09-14 | Univ Of Tokyo | 組織fish法によるテロメア量を指標とした癌の診断 |
JP4635196B2 (ja) * | 2005-03-04 | 2011-02-16 | 国立大学法人広島大学 | 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法 |
RU2007137122A (ru) * | 2005-03-09 | 2009-04-20 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем (Us) | НОВЫЙ ПРОМОТОР hTMC И ВЕКТОРЫ ДЛЯ ОПУХОЛЕСЕЛЕКТИВНОЙ И ВЫСОКОЭФФЕКТИВНОЙ ЭКСПРЕССИИ ТЕРАПЕВТИЧЕСКИХ ПРОТИВОРАКОВЫХ ГЕНОВ |
EP1886138A4 (en) * | 2005-05-11 | 2009-04-15 | Genetic Technologies Ltd | PROCESS FOR ENRICHING FETTAL CELLS |
EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
ES2672205T3 (es) | 2005-12-21 | 2018-06-13 | Université Catholique de Louvain | Células madre hepáticas aisladas |
WO2007149182A2 (en) | 2006-06-19 | 2007-12-27 | Geron Corporation | Differentiation and enrichment of islet-like cells from human pluripotent stem cells |
WO2008002285A1 (en) * | 2006-06-26 | 2008-01-03 | Science Applications International Corporation | Igy antibodies to human telomerase reverse transcriptase |
US20080131442A1 (en) * | 2006-06-26 | 2008-06-05 | Science Applications International Corporation | IgY antibodies to human telomerase reverse transcriptase |
AU2013203229C1 (en) * | 2006-07-28 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
CN105132439A (zh) | 2006-07-28 | 2015-12-09 | 宾夕法尼亚大学托管会 | 改进的疫苗及其使用方法 |
ES2376010T3 (es) * | 2006-10-12 | 2012-03-08 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Prote�?na de fusión de transcriptasa inversa de la telomerasa, nucleótidos que la codifican y usos de la misma. |
EP2088864B1 (en) | 2006-11-03 | 2017-08-16 | The Board of Trustees of the Leland Stanford Junior University | Selective immunodepletion of endogenous stem cell niche for engraftment |
EP1994942A1 (en) * | 2007-05-25 | 2008-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions comprising telomerase, and uses thereof |
ES2751997T3 (es) | 2008-01-14 | 2020-04-02 | Conventus Orthopaedics Inc | Aparato de reparación de fracturas |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9447467B2 (en) | 2009-04-21 | 2016-09-20 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
US20110014161A1 (en) * | 2009-07-09 | 2011-01-20 | Xiaozhen Wang | Cardiac Tissue-Derived Cells |
US20110178520A1 (en) | 2010-01-15 | 2011-07-21 | Kyle Taylor | Rotary-rigid orthopaedic rod |
CN102821707B (zh) | 2010-01-20 | 2016-02-03 | 康文图斯整形外科公司 | 用于骨接近和骨腔准备的装置及方法 |
US9249452B2 (en) * | 2010-02-26 | 2016-02-02 | Zhu Zhen Pirot | Method of detecting and assaying telomerase activity of telomerase bound by anti-telomerase antibodies |
CN105361942B (zh) | 2010-03-08 | 2018-01-09 | 康文图斯整形外科公司 | 用于固定骨植入物的装置及方法 |
AU2011236653B2 (en) | 2010-04-08 | 2016-10-27 | The University Court Of The University Of Edinburgh | Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
WO2012026309A1 (ja) * | 2010-08-23 | 2012-03-01 | 公立大学法人横浜市立大学 | 抗pad4抗体医薬の創成 |
CN102093980B (zh) * | 2010-12-10 | 2013-04-17 | 梁伟国 | 永生化人椎间盘髓核细胞体系的制备方法 |
US8420617B2 (en) * | 2011-03-11 | 2013-04-16 | Biocell Laboratories | Multiantivirus compound, composition and method for treatment of virus diseases |
CN102676518B (zh) * | 2012-02-27 | 2013-09-18 | 华侨大学 | 一种新型抗肿瘤amiRNA序列及其应用 |
EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
US9730984B2 (en) * | 2012-05-11 | 2017-08-15 | Gemvax & Kael Co., Ltd. | Composition for preventing or treating rheumatoid arthritis |
KR20210025132A (ko) * | 2012-05-11 | 2021-03-08 | 주식회사 젬백스앤카엘 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 |
US10900072B2 (en) * | 2012-06-27 | 2021-01-26 | Rutgers, The State University Of New Jersey | Rapid assays for T-cell activation by RNA measurements using flow cytometry |
US20150125438A1 (en) * | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
CN110028554B (zh) * | 2012-09-19 | 2023-04-07 | 珍白斯凯尔有限公司 | 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 |
ES2802253T3 (es) * | 2012-09-19 | 2021-01-18 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
KR102038487B1 (ko) | 2012-09-19 | 2019-10-30 | 주식회사 젬백스앤카엘 | 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물 |
KR102166542B1 (ko) | 2012-09-28 | 2020-10-16 | 주식회사 젬백스앤카엘 | 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제 |
KR102093093B1 (ko) | 2012-12-13 | 2020-03-25 | 주식회사 젬백스앤카엘 | 피부 노화 개선용 조성물 |
KR102106756B1 (ko) | 2012-12-13 | 2020-05-06 | 주식회사 젬백스앤카엘 | 자외선에 의한 피부 손상 예방 또는 치료용 조성물 |
AU2014218667A1 (en) | 2013-02-22 | 2015-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
US10138488B2 (en) | 2013-03-28 | 2018-11-27 | Invectys | Cancer vaccine for dogs |
US9931387B2 (en) | 2013-03-28 | 2018-04-03 | Invectys | Cancer vaccine for cats |
MX2015017103A (es) | 2013-06-11 | 2016-11-07 | Harvard College | Celulas beta derivadas de células madre ( sc-beta ) y composiciones y métodos para generarlas. |
CN106061509B (zh) | 2013-10-28 | 2022-04-08 | 英韦克泰斯公司 | 编码端粒酶的dna疫苗 |
JP6601915B2 (ja) | 2013-10-28 | 2019-11-06 | アンヴェクティ | 皮膚細胞への電気的遺伝子導入 |
EP2871235A1 (en) * | 2013-11-07 | 2015-05-13 | Centre National de la Recherche Scientifique (CNRS) | New methods to produce active hTERT |
AU2014362251B2 (en) | 2013-12-12 | 2019-10-10 | Conventus Orthopaedics, Inc. | Tissue displacement tools and methods |
KR102166549B1 (ko) | 2014-01-10 | 2020-10-16 | 주식회사 젬백스앤카엘 | 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
SI3656869T1 (sl) | 2014-08-26 | 2021-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | Vsaditev matičnih celic s kombinacijo sredstva, ki cilja matične celice in modulacija imunoregulatornega signaliziranja |
EP3370764A4 (en) | 2015-11-05 | 2019-07-17 | The Regents of The University of California | CELLS MARKED BY LIPID CONJUGATES AND METHODS OF USING THE SAME |
AU2017208848A1 (en) | 2016-01-19 | 2018-07-12 | Pfizer Inc. | Cancer vaccines |
CN110312527A (zh) | 2017-01-30 | 2019-10-08 | 小利兰·斯坦福大学托管委员会 | 用于干细胞移植的非基因毒性预处理方案 |
US10631881B2 (en) | 2017-03-09 | 2020-04-28 | Flower Orthopedics Corporation | Plating depth gauge and countersink instrument |
US11351246B2 (en) | 2017-05-09 | 2022-06-07 | Invectys SAS | Recombinant measles vaccine expressing hTERT |
WO2019010252A2 (en) | 2017-07-04 | 2019-01-10 | Conventus Orthopaedics, Inc. | APPARATUS AND METHODS FOR TREATING BONES |
US11786557B2 (en) | 2017-10-02 | 2023-10-17 | Fred Hutchinson Cancer Center | Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells |
CN108715863B (zh) * | 2018-05-30 | 2020-09-11 | 吉林大学 | 一种肿瘤靶向性载体pcTERT及其构建方法及其应用 |
CN110827920B (zh) * | 2018-08-14 | 2022-11-22 | 武汉华大医学检验所有限公司 | 测序数据分析方法和设备及高通量测序方法 |
CN112930404A (zh) * | 2018-09-05 | 2021-06-08 | 瑞德库尔有限责任公司 | 用于治疗剂分析的方法和系统 |
AU2019333905A1 (en) * | 2018-09-06 | 2021-03-04 | The Board Of Regents Of The University Of Texas System | Telomerase holoenzyme complex and methods of use thereof |
CN109545039A (zh) * | 2019-01-15 | 2019-03-29 | 苏州大学 | 一种核孔复合体结构模型教具及其使用方法 |
CA3145681A1 (en) | 2019-07-05 | 2021-01-14 | Case Western Reserve University | Priming media and methods for stem cell culture and therapy |
JP2021151979A (ja) * | 2020-03-24 | 2021-09-30 | 均 石井 | 再生医療薬 |
CN112063601B (zh) * | 2020-09-22 | 2023-06-02 | 浙江愈方生物科技有限公司 | 一种灭活性端粒酶、具有其的腺病毒和人造mRNA及应用 |
JP2022151412A (ja) * | 2021-03-23 | 2022-10-07 | 均 石井 | 脳卒中治療薬 |
CN113355303B (zh) * | 2021-06-07 | 2023-06-16 | 中元汇吉生物技术股份有限公司 | 一种m-mlv逆转录酶突变体及其应用 |
WO2023141534A1 (en) * | 2022-01-19 | 2023-07-27 | Northwestern University | Agents that target telomerase reverse transcriptase (tert) for treating cancer and sensitizing cancer cells to genotoxic therapy |
CN114920802B (zh) * | 2022-05-16 | 2023-05-23 | 中国地质大学(武汉) | 调节端粒酶限速蛋白运动的多肽探针及其复合物和方法 |
CN116364195B (zh) * | 2023-05-10 | 2023-10-13 | 浙大城市学院 | 一种基于预训练模型的微生物遗传序列表型预测方法 |
Family Cites Families (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US912629A (en) | 1908-08-29 | 1909-02-16 | Conrad L Stueber | Foundation-top for pipe-carriers. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4254082A (en) | 1978-06-12 | 1981-03-03 | Miles Laboratories, Inc. | Specific binding-adsorbent assay test means |
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
JPS57502090A (ru) | 1980-07-18 | 1982-11-25 | ||
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
US5055556A (en) | 1981-10-06 | 1991-10-08 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | Fluorescent conjugates for analysis of molecules and cells |
JPS58215453A (ja) | 1982-06-09 | 1983-12-14 | Toray Silicone Co Ltd | 室温硬化後塗装可能なオルガノポリシロキサン組成物 |
FR2542494B1 (fr) | 1983-03-08 | 1985-08-16 | Sevylor International | Combinaison protectrice, utilisable notamment en atmosphere irradiee |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5272065A (en) | 1983-10-20 | 1993-12-21 | Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
GB8612087D0 (en) | 1986-05-19 | 1986-06-25 | Ici Plc | Hybridisation probes |
US5001225A (en) | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
US4889806A (en) | 1987-04-15 | 1989-12-26 | Washington University | Large DNA cloning system based on yeast artificial chromosomes |
US5017478A (en) | 1987-07-16 | 1991-05-21 | Berlex Laboratories, Inc. | Transfected cells containing plasmids having genes oriented in opposing directions and methods of using |
US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5093245A (en) | 1988-01-26 | 1992-03-03 | Applied Biosystems | Labeling by simultaneous ligation and restriction |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5075227A (en) * | 1989-03-07 | 1991-12-24 | Zymogenetics, Inc. | Directional cloning |
JPH02307059A (ja) | 1989-05-23 | 1990-12-20 | Seiko Instr Inc | 反応容器 |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US5437994A (en) | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
DE69027683T2 (de) | 1989-12-01 | 1997-02-13 | Pharming Bv | Herstellung rekombinanter polypeptide durch rinder und transgene methoden |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
DE69034135T3 (de) | 1989-12-22 | 2012-08-23 | Laboratoires Serono S.A. | DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen |
EP0466874A1 (fr) | 1990-02-09 | 1992-01-22 | Asulab S.A. | Micromoteur electrostatique a champ radial realise par microfabrication photolithographique et procede de realisation d'un tel micromoteur |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
SE468913B (sv) | 1990-05-16 | 1993-04-05 | Igesto Ab | Saekerhetskrok |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
KR100198659B1 (ko) | 1996-05-16 | 1999-06-15 | 구본준 | 메모리 셀, 메모리 장치 및 그의 제조 방법 |
JP2904583B2 (ja) | 1991-10-11 | 1999-06-14 | プロメガ・コーポレーション | 真核無細胞抽出物中での転写と翻訳の共役 |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
AU687736B2 (en) | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
US5489508A (en) * | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
US5645986A (en) | 1992-05-13 | 1997-07-08 | Board Of Reagents, The University Of Texas System | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5648215A (en) | 1992-05-13 | 1997-07-15 | Board Of Regents, The University Of Texas System | Telomerase diagnostic methods |
US5639613A (en) | 1992-05-13 | 1997-06-17 | Board Of Regents, University Of Texas System | Methods for cancer diagnosis and prognosis |
EP0654077A4 (en) | 1992-07-17 | 1996-03-13 | Ribozyme Pharm Inc | PROCESS AND REAGENT FOR THE TREATMENT OF DISEASES IN ANIMALS. |
US6107062A (en) | 1992-07-30 | 2000-08-22 | Inpax, Inc. | Antisense viruses and antisense-ribozyme viruses |
GB2273932A (en) | 1992-11-24 | 1994-07-06 | Stiefel Laboratories | Stable oligonucleotides |
WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
JPH08508636A (ja) | 1993-01-27 | 1996-09-17 | オンコール インコーポレーテッド | 核酸配列の増幅 |
US6140087A (en) | 1993-06-24 | 2000-10-31 | Advec, Inc. | Adenovirus vectors for gene therapy |
US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
US6120764A (en) | 1993-06-24 | 2000-09-19 | Advec, Inc. | Adenoviruses for control of gene expression |
WO1995013382A1 (en) * | 1993-11-12 | 1995-05-18 | Geron Corporation | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
HUT78054A (hu) * | 1994-07-07 | 1999-07-28 | Geron Corporation | Emlőseredetű telomeráz RNS-összetevője |
US5597697A (en) | 1994-09-30 | 1997-01-28 | Diamond; Paul | Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases |
US5698686A (en) | 1994-10-20 | 1997-12-16 | Arch Development Corporation | Yeast telomerase compositions |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
JPH10513343A (ja) * | 1994-12-19 | 1998-12-22 | コールド スプリング ハーバー ラボラトリー | テロメラーゼの蛋白質成分 |
US5741677A (en) | 1995-06-07 | 1998-04-21 | Geron Corporation | Methods for measuring telomere length |
WO1997015687A1 (en) | 1995-06-07 | 1997-05-01 | Geron Corporation | Telomerase activity assays |
EP0832190A1 (en) | 1995-06-07 | 1998-04-01 | Cold Spring Harbor Laboratory | Essential oligonucleotides of vertebrate telomerase |
US5722998A (en) | 1995-06-07 | 1998-03-03 | Intermedics, Inc. | Apparatus and method for the control of an implantable medical device |
US5968506A (en) | 1995-08-04 | 1999-10-19 | Geron Corporation | Purified telomerase |
US6517834B1 (en) | 1995-08-04 | 2003-02-11 | Geron Corporation | Purified telomerase |
US6545133B1 (en) | 1995-08-04 | 2003-04-08 | Geron Corporation | Methods for purifying telomerase |
DE69524247T2 (de) | 1995-08-04 | 2002-08-08 | Ibm | Stempel für lithographie-verfahren |
JPH09154575A (ja) | 1995-10-04 | 1997-06-17 | Soosei:Kk | テロメラーゼ |
JPH09164575A (ja) | 1995-12-13 | 1997-06-24 | Japan Steel Works Ltd:The | 流れ模様を有する樹脂板の製造方法およびその装置 |
US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
US5747317A (en) | 1996-07-08 | 1998-05-05 | Tularik Inc. | Human telomerase RNA interacting protein gene |
US5770422A (en) | 1996-07-08 | 1998-06-23 | The Regents Of The University Of California | Human telomerase |
US5724021A (en) | 1996-07-09 | 1998-03-03 | Stephen C. Perrone | Self-contained, programmable, time interval alarm reminder device for eyedrop medication administration and a means for affixing such to eyedrop/medication container |
WO1998007838A1 (fr) | 1996-08-21 | 1998-02-26 | Mitsubishi Chemical Corporation | Proteine de telomerase d'animaux superieurs et gene codant pour elle |
WO1998008938A1 (en) | 1996-08-28 | 1998-03-05 | Shonen Yoshida | Proteins having telomerase activity |
DE19638482A1 (de) | 1996-09-20 | 1998-04-02 | Bosch Gmbh Robert | Verfahren zur Auswahl einer Sendefrequenz |
US6767719B1 (en) | 1997-11-26 | 2004-07-27 | Geron Corporation | Mouse telomerase reverse transcriptase |
US6777203B1 (en) | 1997-11-19 | 2004-08-17 | Geron Corporation | Telomerase promoter driving expression of therapeutic gene sequences |
US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6808880B2 (en) | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
EP0954585B1 (en) | 1996-10-01 | 2009-11-25 | Geron Corporation | Human telomerase reverse transcriptase promoter |
US5890326A (en) | 1996-11-06 | 1999-04-06 | Hill-Rom, Inc. | Head wall for a hospital room |
US7390891B1 (en) * | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
US5919656A (en) | 1996-11-15 | 1999-07-06 | Amgen Canada Inc. | Genes encoding telomerase protein 1 |
EP0942991A2 (en) | 1996-11-26 | 1999-09-22 | Baylor College Of Medicine | Identification of inhibitors that prevent access of telomerase to chromosomal terminus |
WO1998037181A2 (en) * | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
US6617119B2 (en) | 1997-02-21 | 2003-09-09 | The Regents Of The University Of California | Assay for specific strains of multiple disease related conformations of a protein |
ES2208895T3 (es) * | 1997-04-04 | 2004-06-16 | Geron Corporation | Telomerasa purificada. |
US6485789B1 (en) | 1997-04-14 | 2002-11-26 | 3M Innovative Properties Company | Fluorochemical composition containing a condensation product of a fluorochemical polyether and a poly-isocyanate to impart stain release properties to a substrate |
US20050013825A1 (en) | 1997-04-18 | 2005-01-20 | Geron Corporation | Vaccine containing the catalytic subunit of telomerase for treating cancer |
US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
US7413864B2 (en) | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
US6201830B1 (en) | 1997-06-11 | 2001-03-13 | Texas Instruments Incorporated | Low computation idle transmission method for DSL modems |
EP0990037A2 (de) * | 1997-06-20 | 2000-04-05 | Bayer Ag | Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung |
KR100581990B1 (ko) | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
US7378244B2 (en) | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
WO1999027113A1 (en) | 1997-11-26 | 1999-06-03 | Geron Corporation | Mouse telomerase reverse transcriptase |
DE19757984A1 (de) | 1997-12-24 | 1999-07-01 | Bayer Ag | Regulatorische DNA-Sequenzen aus der 5'-Region vom Gen der humanen katalytischen Telomerase-Untereinheit udn deren diagnostische und therapeutische Verwendung |
US6608188B1 (en) | 1998-01-08 | 2003-08-19 | Chugai Seiyaku Kabushiki Kaisha | CRT-1 gene having reverse transcriptase motif |
GB9801902D0 (en) | 1998-01-29 | 1998-03-25 | Cancer Res Campaign Tech | A gene promoter |
US6337200B1 (en) * | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
JP2002509716A (ja) | 1998-03-31 | 2002-04-02 | ユニバーシティ テクノロジー コーポレイション | テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物 |
CA2331378A1 (en) | 1998-06-12 | 1999-12-16 | Sloan-Kettering Institute For Cancer Research | Vaccination strategy to prevent and treat cancers |
US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
EP1147181B1 (en) | 1999-02-04 | 2004-05-12 | Geron Corporation | Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer |
CA2368967A1 (en) | 1999-04-09 | 2000-10-19 | Biomira, Inc. | Telomerase-specific cancer vaccine |
WO2000073420A2 (en) | 1999-06-02 | 2000-12-07 | Whitehead Institute For Biomedical Research | Creation of human tumorigenic cells and uses therefor |
US6354941B2 (en) | 1999-11-03 | 2002-03-12 | 516 Holdings | Electronic system for a game of chance |
CA2399816A1 (en) | 2000-02-15 | 2001-08-23 | Regents Of The University Of California | A universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
US7262174B2 (en) | 2001-05-09 | 2007-08-28 | Geron Corporation | Treatment for wounds |
JP2002348474A (ja) | 2001-05-23 | 2002-12-04 | Dow Corning Toray Silicone Co Ltd | ポリオルガノシロキサンマイクロエマルジョン組成物および化粧料原料 |
US20030143228A1 (en) | 2001-10-29 | 2003-07-31 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen |
US7294708B2 (en) | 2002-05-31 | 2007-11-13 | Beijing Institute Of Biotechnology | Telomerase reverse transcriptase fragments and uses thereof |
KR100705868B1 (ko) | 2003-05-06 | 2007-04-10 | 후지 덴키 디바이스 테크놀로지 가부시키가이샤 | 반도체 장치 및 그 제조 방법 |
-
1997
- 1997-10-01 EP EP97910785A patent/EP0954585B1/en not_active Expired - Lifetime
- 1997-10-01 CA CA2645721A patent/CA2645721C/en not_active Expired - Lifetime
- 1997-10-01 CN CN201010150493.9A patent/CN102021153B/zh not_active Expired - Lifetime
- 1997-10-01 EP EP97307757A patent/EP0841396B2/en not_active Expired - Lifetime
- 1997-10-01 EP EP20090176870 patent/EP2213740A1/en not_active Withdrawn
- 1997-10-01 GB GB9720890.4A patent/GB2317891C/en not_active Expired - Lifetime
- 1997-10-01 AU AU48073/97A patent/AU734089B2/en not_active Expired
- 1997-10-01 GB GB9804859A patent/GB2321642B8/en not_active Expired - Lifetime
- 1997-10-01 BR BR9711844-3A patent/BR9711844A/pt unknown
- 1997-10-01 KR KR1019990702815A patent/KR20000048820A/ko not_active Application Discontinuation
- 1997-10-01 CA CA2267664A patent/CA2267664C/en not_active Expired - Lifetime
- 1997-10-01 IL IL12922297A patent/IL129222A0/xx unknown
- 1997-10-01 CN CN97199534A patent/CN1254376A/zh active Pending
- 1997-10-01 SG SG200101834A patent/SG94355A1/en unknown
- 1997-10-01 EA EA199900355A patent/EA199900355A1/ru unknown
- 1997-10-01 AT AT97307757T patent/ATE245194T1/de active
- 1997-10-01 JP JP51680298A patent/JP2001523947A/ja active Pending
- 1997-10-01 BR BR9712254-8A patent/BR9712254A/pt not_active IP Right Cessation
- 1997-10-01 EP EP03075454A patent/EP1333094B1/en not_active Expired - Lifetime
- 1997-10-01 AT AT03075454T patent/ATE552341T1/de active
- 1997-10-01 WO PCT/US1997/017885 patent/WO1998014593A2/en not_active Application Discontinuation
- 1997-10-01 DE DE19743497A patent/DE19743497A1/de not_active Withdrawn
- 1997-10-01 CA CA002266752A patent/CA2266752A1/en not_active Abandoned
- 1997-10-01 DE DE69739675T patent/DE69739675D1/de not_active Expired - Lifetime
- 1997-10-01 AU AU48036/97A patent/AU4803697A/en not_active Abandoned
- 1997-10-01 DE DE69739497T patent/DE69739497D1/de not_active Expired - Lifetime
- 1997-10-01 EP EP06117664A patent/EP1783139B8/en not_active Expired - Lifetime
- 1997-10-01 EA EA199900349A patent/EA199900349A1/ru unknown
- 1997-10-01 EP EP97910737A patent/EP0932686A2/en not_active Withdrawn
- 1997-10-01 DE DE0841396T patent/DE841396T1/de active Pending
- 1997-10-01 IL IL12910397A patent/IL129103A0/xx not_active IP Right Cessation
- 1997-10-01 JP JP28618297A patent/JP3869092B2/ja not_active Expired - Lifetime
- 1997-10-01 DE DE69723531T patent/DE69723531T3/de not_active Expired - Lifetime
- 1997-10-01 CN CN971802564A patent/CN1291231B/zh not_active Expired - Lifetime
- 1997-10-01 BR BRPI9712254A patent/BRPI9712254B1/pt unknown
- 1997-10-01 ES ES97307757T patent/ES2205132T5/es not_active Expired - Lifetime
- 1997-10-01 JP JP51690998A patent/JP2001510985A/ja active Pending
- 1997-10-01 WO PCT/US1997/017618 patent/WO1998014592A2/en not_active Application Discontinuation
- 1997-10-01 NZ NZ334709A patent/NZ334709A/en not_active IP Right Cessation
- 1997-10-01 FR FR9712217A patent/FR2757177A1/fr active Pending
- 1997-10-01 AT AT97910785T patent/ATE449851T1/de not_active IP Right Cessation
- 1997-10-01 KR KR1019997002838A patent/KR100530483B1/ko not_active IP Right Cessation
- 1997-11-19 US US08/974,549 patent/US6166178A/en not_active Expired - Lifetime
-
1998
- 1998-10-15 JP JP32016998A patent/JP4070331B2/ja not_active Expired - Lifetime
-
1999
- 1999-02-19 JP JP11042410A patent/JPH11313689A/ja active Pending
- 1999-03-24 FI FI990655A patent/FI990655A0/fi unknown
- 1999-03-31 NO NO19991588A patent/NO319982B1/no not_active IP Right Cessation
-
2000
- 2000-07-27 JP JP2000227474A patent/JP2001081042A/ja not_active Withdrawn
- 2000-11-22 US US09/721,456 patent/US6617110B1/en not_active Expired - Lifetime
- 2000-11-22 US US09/721,477 patent/US7517971B1/en not_active Expired - Fee Related
-
2005
- 2005-06-24 NO NO20053120A patent/NO332085B1/no unknown
-
2007
- 2007-08-20 US US11/894,600 patent/US8222392B2/en not_active Expired - Fee Related
-
2008
- 2008-07-28 JP JP2008194208A patent/JP4852576B2/ja not_active Expired - Lifetime
-
2011
- 2011-10-18 HK HK11111117.2A patent/HK1156967A1/zh not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2581800C2 (ru) * | 2010-02-16 | 2016-04-20 | Ультимовакс Ас | Полипептиды |
US9657068B2 (en) | 2010-02-16 | 2017-05-23 | Ultimovacs As | Telomerase polypeptide vaccine for treating cancer |
US10383928B2 (en) | 2010-02-16 | 2019-08-20 | Ultimovacs As | Telomerase polypeptide vaccine for treating cancer |
US11529403B2 (en) | 2010-02-16 | 2022-12-20 | Ultimovacs As | Telomerase polypeptide vaccine for treating cancer |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA199900349A1 (ru) | Каталитическая субъединица теломеразы человека | |
TR199901971T2 (xx) | Bir resept�re ba�lanan peptidler ve bile�ikler. | |
DE60136099D1 (de) | Zusammensetzungen zur behandlung und diagnose von eierstockkrebs | |
PT991421E (pt) | Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa | |
NZ512247A (en) | Compositions and methods for therapy and diagnosis of ovarian cancer | |
AR006250A1 (es) | Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico | |
NO20002979D0 (no) | Undersøkelse av human papillomavirus-relatert sykdom | |
DE60039752D1 (de) | Herstellung tetravalenter antikörper | |
ES2148171T3 (es) | Gen mutado en cancer colorrectal de humanos. | |
BR9807734A (pt) | Composto para imunodiagnose de câncer de próstata e métodos para o uso dos memos | |
RU2001104349A (ru) | Композиции и способы для терапии и диагностики рака предстательной железы | |
EA199800692A1 (ru) | Изолируемые смеси из семян eugenia jambolana lamarck, способы их получения, способ получения оксамата натрия, лекарственные средства для профилактики и лечения диабета и применение указанных смесей, их компонентов и оксамата натрия для получения этих лекарственных средств | |
WO2001018046A3 (en) | Ovarian tumor sequences and methods of use therefor | |
WO2004047757A3 (en) | Diagnosing and treating hematopoietic cancers | |
DE69942637D1 (de) | Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs | |
WO1999064869A3 (en) | Back pain diagnosis and apparatus for use therein | |
ATE542900T1 (de) | Icbp90-polypeptide, polypeptidfragmente davon, die dafür kodierenden polynukleotide, und ihre verwendung zur behandlung und diagnose von krebs | |
BR1100558A (pt) | famìlia de anticorpos modificados, com elevada afinidade, para tratamento de cáncer. | |
WO2000056351A3 (en) | Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms |